Merck profit beats, but Keytruda sales fail to impress
By Manas Mishra (Reuters) - Merck & Co beat quarterly profit estimates on Friday as sales of its blockbuster drug Keytruda overtook rival Bristol-Myers Squibb's Opdivo, but that was not enough for investors who expected bigger gains in market share for the cancer therapy. Shares of the Dow component fell as much as 2.5 percent, with the company sticking to its decision to keep the animal health unit unlike rival Eli Lilly, which plans to take its unit public.
By Manas Mishra
(Reuters) - Merck & Co beat quarterly profit estimates on Friday as sales of its blockbuster drug Keytruda overtook rival Bristol-Myers Squibb's Opdivo, but that was not enough for investors who expected bigger gains in market share for the cancer therapy.
Shares of the Dow component fell as much as 2.5 percent, with the company sticking to its decision to keep the animal health unit unlike rival Eli Lilly, which plans to take its unit public.
"They're (Merck) going in the right direction and in the next couple of quarters they are going to gain more market share from Bristol, but maybe it's taking a little longer than expected," Jeff Jonas, a portfolio manager at Gabelli Funds that owns shares of Merck, said.
Keytruda sales surged 89.2 percent to $1.67 billion. Analysts had expected sales of $1.59 billion, according to Credit Suisse.
Both Keytruda and Bristol's Opdivo work by triggering the immune system to attack tumors but Merck leads in lung cancer treatments, both alone and in combination with chemotherapy.
Merck's total sales rose 5.4 percent to $10.47 billion. The company also raised full-year forecast for adjusted earnings per share and now expects it to be between $4.22 and $4.30, up from prior guidance of between $4.16 and $4.28.
Excluding items, the company earned $1.06 per share, ahead of the average analyst estimate of $1.03 per share, according to Thomson Reuters I/B/E/S.
ANIMAL HEALTH PLAN
Merck in the past has called the animal health unit, whose sales rose 14.1 percent to $1.09 billion in the quarter, a "pillar of growth" as it provides diversification away from Keytruda.
"We see animal health still fitting with our strategic intent," Chief Executive Officer Kenneth Frazier said.
Much before Lilly moved to take its animal health business public, bigger rival Pfizer Inc had done the same with Zoetis Inc five years ago and since then its market value has tripled.
"Many investors had hoped that Lilly's recent announcement would have been the final tipping point to cause Merck to do the same," Brad Loncar, chief executive officer of Loncar Investments, which runs the Loncar Cancer Immunotherapy ETF, said.
Shares of the company were trading down 1 percent at $63.40 in midday trading.
(Reporting by Manas Mishra in Bengaluru and Michael Erman in New York; Editing by Arun Koyyur)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
By Guy Faulconbridge and Kate Holton LONDON (Reuters) - Rich countries could be back to close to normal by late 2021 if a COVID-19 vaccine works, is ready soon and distributed properly at scale, Microsoft founder Bill Gates said on Tuesday. "By late next year you can have things going back pretty close to normal - that's the best case," Gates, 64, told The Wall Street Journal CEO Council. "We still don't know whether these vaccines will succeed," Gates said.
By Rupam Jain (Reuters) - Taliban and Afghan government-backed negotiators have agreed on a broad code of conduct to advance the intra-Afghan peace talks in Qatar, even as key differences between the two warring sides remain, three official sources told Reuters on Tuesday.
MOSCOW (Reuters) - Russian rights groups on Tuesday called on the authorities to stop using home searches as a tactic to intimidate opponents after a journalist set herself on fire following a police raid of her apartment last week. Irina Slavina, editor-in-chief at a small news outlet in the city of Nizhny Novgorod, self-immolated in front of the local branch of the interior ministry in Nizhny Novgorod last Friday after blaming Russian authorities for her death in a Facebook post